- PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE
-
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
- -
-
Paragraph 00237; 00276-00287
(2019/05/02)
-
- Structure - activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4, 5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding
-
The EP3 receptor on the platelet mediates prostaglandin E 2 potentiation of thrombogenic coagonists including collagen and adenosine diphosphate (ADP). A pharmacophore driven approach led to the identification of diverse peri-substituted heterocycles as potent and selective EP3 receptor antagonists. A simultaneous chemical optimization and druglike assessment of prioritized molecules converged on a lead compound 50 (DG-041) that displayed favorable in vitro and functional activities as an inhibitor of human platelet aggregation. This agent is currently in human clinical trials for the treatment of atherothrombosis.
- Singh, Jasbir,Zeller, Wayne,Zhou, Nian,Hategan, Georgeta,Mishra, Rama K.,Polozov, Alex,Yu, Peng,Onua, Emmanuel,Zhang, Jun,Ramírez, José L.,Sigthorsson, Gudmundur,Thorsteinnsdottir, Margret,Kiselyov, Alex S.,Zembower, David E.,Andrésson, Thorkell,Gurney, Mark E.
-
experimental part
p. 18 - 36
(2010/04/26)
-
- Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of "magic mushroom"
-
The concise large-scale syntheses of psilocin (1) and psilocybin (2), the principal hallucinogenic constituents of "magic mushroom", were achieved without chromatographic purification. The key step in the synthesis of 2 was the isolation of the dibenzyl-protected intermediate (7) as a zwitterionic derivative (8), which was completely identified by means of 2D NMR analyses.
- Shirota, Osamu,Hakamata, Wataru,Goda, Yukihiro
-
p. 885 - 887
(2007/10/03)
-
- Process for the preparation of 5,6-diacetoxyindole
-
An indole of the formula STR1 wherein R5 and R6 are acetoxy or hydrogen, at least one of R5 and R6 being acetoxy, is prepared, in good yield, in a one pot synthesis, without extraction, recrystallization or isolation of intermediate reaction product; A compound of the formula STR2 wherein R1 and R2 are benzyloxy or hydrogen, provided that at least one of R1 and R2 is benzyloxy, is subjected to reductive cyclization followed by acetylation of the resultant reaction product.
- -
-
-
